Formic Acid

Formic Acid

SCHEMBL3544409

N=C(N)Nc1nc2c(s1)CCCC2C(=O)NCc1ccccc1.O=CO

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 4/20 0.41
P2RX7 Q99572 2/20 0.40
ADRB3 P13945 2/20 0.39
ALDH1A1 P00352 3/20 0.39
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
XIAP P98170 2/20 0.39
DRD2 P14416 1/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
LIMK1 P53667 1/20 0.38
ALOX5 P09917 1/20 0.38
MAPT P10636 3/20 0.38
GAA P10253 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13314793 0.96 F2 (0.44) F2P2RX7ADRB3ALDH1A1USP2
SCHEMBL3536190 0.96 F2 (0.44) F2P2RX7ADRB3ALDH1A1USP2
Formic Acid SCHEMBL3537792 0.87 KRAS (0.46) ADRB3HPGDXIAP
Formic Acid SCHEMBL3540804 0.83 XIAP (0.35) ADRB3XIAPRAB9ANPC1SMN1; SMN2
Formic Acid SCHEMBL3537527 0.83 GAA (0.35) ADRB3XIAPGAA
SCHEMBL13314798 0.82 KRAS (0.49) ADRB3HPGDXIAP
SCHEMBL3533256 0.82 KRAS (0.49) ADRB3HPGDXIAP
Formic Acid SCHEMBL3539296 0.82 ALDH1A1 (0.37) ADRB3ALDH1A1MAPTGAARAB9A
Formic Acid SCHEMBL3537717 0.80 XIAP (0.38) ADRB3XIAPMAPTGAARAB9A
SCHEMBL6211289 0.80 MAPT (0.38) F2ALDH1A1DRD2HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727979-B2 Guanidine derivatives and their use as neuropeptide FF receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-01 US disclosed
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists NPFFR1, OGFR, NPFFR2 F2 809/4885P2RX7 834/4885ADRB3 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.